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Abstract: While the toxicity of metals and metalloids, like arsenic, cadmium, mercury, 
lead and chromium, is undisputed, the underlying molecular mechanisms are not entirely 
clear. General consensus holds that proteins are the prime targets; heavy metals interfere 
with the physiological activity of specific, particularly susceptible proteins, either by 
forming a complex with functional side chain groups or by displacing essential metal ions 
in metalloproteins. Recent studies have revealed an additional mode of metal action 
targeted at proteins in a non-native state; certain heavy metals and metalloids have been 
found to inhibit the in vitro refolding of chemically denatured proteins, to interfere with 
protein folding in vivo and to cause aggregation of nascent proteins in living cells. 
Apparently, unfolded proteins with motile backbone and side chains are considerably more 
prone to engage in stable, pluridentate metal complexes than native proteins with their 
well-defined 3D structure. By interfering with the folding process, heavy metal ions and 
metalloids profoundly affect protein homeostasis and cell viability. This review describes 
how heavy metals impede protein folding and promote protein aggregation, how cells 
regulate quality control systems to protect themselves from metal toxicity and how metals 
might contribute to protein misfolding disorders. 
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1. Introduction 
Heavy metals comprise a loosely defined group of elements that include transition metals and some 
metalloids. These elements affect cells and living organisms in various ways; some heavy metals have 
essential functions (e.g., iron, zinc, copper, manganese) and are toxic only in an overdose, whereas 
others are xenobiotic and highly toxic (e.g., arsenic, cadmium, lead, mercury). Thus, all cells and 
organisms maintain metal homeostasis within physiological or sub-toxic levels, respectively, and 
utilize metal detoxification mechanisms [1,2]. The toxicity of a given metal depends on its 
physicochemical properties and ligand preferences. “Soft” transition metals, like cadmium and 
mercury, prefer sulfur as their ligand. “Hard” transition metals, like chromium and manganese, and the 
metalloids, arsenic, antimony and selenium, favor oxygen in their higher oxidation states and sulfur in 
their lower oxidation states. Lead, iron, cobalt, nickel, copper and zinc may use oxygen, sulfur or 
nitrogen as ligands [2,3]. At the cellular level, heavy metals and metalloids have been reported: (1) to 
generate reactive oxygen species and to elicit oxidative stress; (2) to cause DNA damage and/or impair 
DNA repair mechanisms; (3) to interfere with membrane function and nutrient assimilation; and (4) to 
perturb protein function and activity [3–5]. At the molecular level, our understanding of how heavy 
metals exert these toxic effects is still rudimentary. There is a general consensus that proteins are key 
targets of heavy metals. Metals interfere with the biological activity of native, folded proteins through 
diverse modes of interaction; they may: (1) bind to free thiols or other functional groups in proteins; 
(2) displace essential metal ions in metalloproteins; or (3) catalyze oxidation of amino acid side  
chains [3,4,6]. Recent studies have now revealed an additional mode of metal action that targets  
non-folded proteins. Heavy metals and metalloids have been shown to inhibit refolding of chemically 
denatured proteins in vitro, to interfere with protein folding in vivo and to cause the aggregation of 
nascent proteins in living cells [7–10]. By interfering with the folding of nascent or non-native 
proteins, heavy metals profoundly affect protein homeostasis and cell viability. 
Proteins participate in virtually every biological process. To function, most proteins fold into a 
strictly defined 3D structure, their native conformation. Misfolded proteins are cytotoxic, as they may 
aggregate and/or interact inappropriately with other cellular components. Numerous neurodegenerative 
and age-related disorders are associated with protein misfolding and aggregation [11–13]. There is 
accumulating evidence that metals might enhance the aggregation propensity of disease-associated 
proteins and promote the progression of certain neurodegenerative diseases through largely unknown 
mechanisms [14–19]. Evolutionarily conserved protein quality-control mechanisms protect cells 
against the harmful accumulation of protein aggregates. These quality-control systems consist of:  
(1) molecular chaperones that assist the folding of proteins into their functional conformation or rescue 
misfolded proteins by partial unfolding, thereby giving them another chance to assume their native 
structure; and of (2) protein degradation pathways, including the proteasome, as well as lysosomal and 
autophagic processes, which clear cells from misfolded and aggregated proteins. The malfunction of 
these quality-control systems may result in disease or cell death [11,20,21]. 
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It is important to note that many proteins require metal ions for proper folding and/or for catalytic 
activity and that protein misfolding and aggregation might occur when the homeostasis of essential 
metal ions, such as iron, copper and zinc, is disturbed [19,22]. The mechanisms of (essential) metal 
homeostasis, metal sensing and metal coordination have been reviewed elsewhere [1,19,22–25].  
Here, we review how heavy metals and metalloids, in particular arsenic, cadmium, mercury, lead and 
chromium, interfere with protein folding, how these agents promote protein aggregation and how 
quality-control systems protect cells from their toxicity. 
2. Impact of Heavy Metals on Native, Correctly Folded Proteins 
Heavy metals and metalloids can bind to native proteins and inhibit their biological activity. For 
example, methylmercury (MeHg) strongly inhibits the activity of yeast L-glutamine:D-fructose-6-phosphate 
amidotransferase, and overexpression of the enzyme confers MeHg resistance to yeast cells, 
suggesting that it is indeed targeted by MeHg [26]. How MeHg inhibits this enzyme has not yet been 
ascertained. Cadmium inhibits human thiol transferases (glutathione reductase, thioredoxin reductase, 
thioredoxin) in vitro, possibly by binding to cysteine residues in their active sites [27]. Inhibition of 
thiol transferases probably leads to increased oxidative stress and cell damage. Cadmium may also 
displace zinc and calcium ions from metalloproteins and zinc finger proteins [28,29]. It is not known, 
however, to what extent this metal exchange contributes to cadmium toxicity. Cadmium has been 
shown to cause DNA damage by targeting the DNA mismatch repair system [30]. Specifically, 
cadmium inhibits the ATPase activity of the Msh2p-Msh6p complex [31], but it is not known whether 
it binds to a specific site or displaces a critical zinc ion. Trivalent arsenic (arsenite, (As(III))) interacts 
with many proteins [32] and is supposed to interfere with their activity, e.g., binding to β-tubulin 
inhibits its polymerization [33]. Likewise, arsenic trioxide (ATO), the form of arsenite used in cancer 
therapy, inhibits mammalian thioredoxin reductase (TrxR), probably by directly binding to the enzyme. 
TrxR inhibition leads to the oxidation of thioredoxin, which is one of the main thiol-dependent 
electron donor systems in mammalian cells, thereby affecting the cellular redox environment and a 
wide range of cellular processes [34]. ATO directly binds to cysteine residues in the PML-RARα 
oncoprotein that is expressed in patients suffering from acute promyelocytic leukemia (APL).  
ATO-binding induces oligomerization and subsequent degradation of the aberrant PML-RARα fusion 
protein, which, in turn, inhibits the growth of APL cells, thereby curing the disease [35,36]. In contrast, 
binding of arsenic to pyruvate kinase M2 does not impair the activity of this enzyme [33]. Moreover, in a 
human cell line, the pyruvate dehydrogenase multi-enzyme complex proved to be more sensitive to 
inhibition by arsenic-induced reactive oxygen species than to direct inhibition by arsenicals [37]. 
Apparently, certain native proteins are more susceptible to metal-induced oxidation than to direct 
metal binding. 
3. Proteins Are Vulnerable during Folding, Be It In Vitro or In Vivo 
Folding in vitro starts with a chemically denatured protein with a spatially undefined random coil 
structure and is initiated by dilution or removal of the denaturing agent, such as urea or guanidinium 
chloride. In vivo folding, however, is a cotranslational process, which starts as soon as an NH2-terminal 
segment of sufficient length has been synthesized and has left the exit tunnel of the ribosome. The first 
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synthesized domain thus acquires 3D structural elements (α-helices, β-sheets and, in part, a tertiary 
structure in a highly motile molten globule state) while the rest of the polypeptide chain is still being 
synthesized on the ribosome [38,39]. 
Experiments on in vitro refolding are usually performed with a purified protein at low 
concentration, i.e., under conditions that maximize the yield of refolding. In contrast, in vivo folding 
occurs in the crowded interior of a cell at a protein concentration of 300–400 mg/mL, which greatly 
enhances the chances of intermolecular interactions, including the aggregation of still incompletely 
folded or misfolded proteins. The folding of many nascent polypeptide chains requires the assistance 
of molecular chaperones as soon as they emerge from the exit tunnel of the ribosome. In particular, 
molecular chaperones (heat shock proteins) of the Hsp70 family and chaperonins (Hsp60) are engaged. 
Chaperones improve the yield of folding of the nascent chains by two different mechanisms: on the 
one hand, they prevent hydrophobic intra- and inter-molecular contacts that might result in misfolding 
and aggregation; on the other hand, they rescue misfolded and aggregated proteins by unfolding  
and giving them another chance to proceed on their correct folding pathway. Irreversibly misfolded 
proteins are eliminated by quality control mechanisms [20,21]. Although the intracellular pathway of 
protein folding is considerably more complex than that of in vitro folding, both roads lead to the 
unique 3D structure of the given protein. 
Intramolecular interactions within the backbone of the polypeptide chain and between its side 
chains are responsible for the stable and strictly defined 3D structure of a given protein. The final, 
functionally active conformation corresponds to the conformational state of lowest free energy and is 
determined solely by the amino acid sequence of the protein [40]. Hydrogen bonds as directed forces 
determine the spatial course of the polypeptide chain, and the hydrophobic effects of apolar side chains 
provide the thermodynamic stability of the 3D structure [41]. The individual molecules of a given 
polypeptide under given conditions (particularly pH, temperature and the type and concentration of salt 
ions) apparently attain their final 3D structure essentially via the same transition states and 
intermediates. The rate of folding depends on the particular protein and varies in a wide range. Small 
proteins (<100 residues) with a single folding domain may reach their final conformation within 
milliseconds, whereas larger multi-domain proteins may require minutes to hours, proline 
isomerization and disulfide isomerization being possible rate-limiting steps [42]. 
Experimental in vitro folding and physiological intracellular in vivo folding share, despite their 
differences, important features; not only an identical end product, the structure of which is determined 
and stabilized by identical interactions, but also intermediary states of folding in which segments of the 
backbone and the side chains are still motile and the functional groups of the side chains are not yet 
shielded from the solute. These features make both in vitro and in vivo folding proteins prone to 
interacting with heavy metal ions and metalloids. 
4. Heavy Metals and Metalloids Interact with Functional Groups of Chemically Denatured 
Proteins and Inhibit Their In Vitro Refolding 
Heavy metal ions, such as Cd
2+
, Hg
2+
 and Pb
2+
, are well known to form relatively labile 
monodentate and highly stable pluridentate complexes with sulfur, nitrogen and oxygen atoms of 
proteins. The values of the apparent dissociation equilibrium constants, Kd’, of the respective 
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monodentate complexes of these metal ions with thiol, imidazole and carboxyl groups, the three most 
important ligands for divalent metal ions in proteins, depend on the particular metal-ligand 
combination and vary over a very broad range from picomolar to millimolar (Table 1). Pluridentate 
(multidentate) complexes are much more stable, their Kd’ values being close to the product of the Kd’ 
values of all the participating monodentate interactions. Such highly stable pluridentate complexes, 
most of them with a tetrahedral (four ligands) or octahedral (eight ligands) geometry, are found  
in metalloproteins [43–45]. 
Table 1. Dissociation equilibrium constants of monodentate metal complexes. 
 
Kd’ at pH 7 * Approximate pKa 
in proteins Cd
2+
 Hg
2+
 Pb
2+
 
Thiol group 2.5 µM 0.063 nM 13 µM 9.4 
Imidazole group 2.0 mM 200 µM 6.3 mM 6.5 
Carboxyl group 16 mM 2.5 µM 13 mM 4.6 
* Kd’is the apparent dissociation equilibrium constant at pH 7 of the reaction ML       M + L, where ML is the 
1:1 complex of the metal ion (M) and ligand (L) [45]. 
The recent observations that Cd
2+
, Hg
2+
, Pb
2+
 and arsenite effectively interfere with the refolding  
of chemically denatured proteins has opened up a novel perspective in metal toxicology [6–9]. Their 
inhibitory effect on the refolding of chemically denatured proteins becomes apparent without delay 
after addition at nanomolar final concentrations. In contrast, native proteins are much less affected by 
metal ions under the same conditions, being inactivated only to a limited degree in a slow time-dependent 
process [7]. Dose-response curves for the inhibition of refolding, i.e., for the decrease in the folding 
yield, indicate IC50 values in the two- to three-digit nanomolar range (Table 2). It is important to  
note that these IC50 values had to be determined at a protein concentration of 350 nM, because the 
reproducibility of measurements at lower concentrations had proven unsatisfactory. The IC50 values 
given in Table 2 are thus strictly apparent values obtained at metal/metalloid concentrations lower than 
the protein concentration; they perforce underestimate the folding-inhibitory effect of the metal ions. 
The example of glucose-6-phosphate dehydrogenase, a cysteine-free enzyme, shows that stable 
chelate-like structures that impede refolding apparently are also formed in proteins lacking cysteine 
residues (Table 2). 
Neither reduced glutathione nor the chelator EDTA rescue the protein that has misfolded in the 
presence of Cd
2+
. In contrast, the ATP-dependent Hsp70 chaperone system (DnaK/DnaJ/GrpE of 
Escherichia coli was used) significantly attenuates the folding-inhibitory effect of metal ions. 
Accordingly, ATP consumption measurements show an increased engagement of the chaperone 
system in the presence of metal ions; during in vitro refolding, metal ions almost double the  
chaperone load [7]. 
The ranking of the metal ions in terms of their efficacy in folding inhibition is Hg
2+
 > Cd
2+
 > Pb
2+
 
(Table 2) and correlates with the relative stability of their monodentate complexes with thiol, 
imidazole and carboxylate groups in proteins (Table 1). The IC50 of both Cd
2+
 and Pb
2+
 are (despite 
being overestimated) two to three orders of magnitude lower than the dissociation equilibrium 
constants of their monodentate complexes with protein side chain groups (very tight binding of Hg
2+
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being an exception, probably due to its grossly underestimated inhibitory effect, i.e., much too high 
apparent IC50, as discussed above). The discrepancy indicates that highly stable pluridentate complexes 
rather than relatively labile monodentate complexes interfere with the proper refolding of the proteins. 
The chances of metal ions to interact with several potential ligands and to form stable pluridentate 
complexes with their metal-specific geometry [43–45] is of course much higher in the case of a 
denatured protein with motile random coil conformation and fully accessible side chain groups than in 
the case of a folded protein with its stable native structure and the side chains in a fixed and, for part of 
them, even buried location. In a folded protein, the formation of pluridentate complexes with specific 
geometry would require its partial unfolding. Compared with the rates of ribosomal protein synthesis 
(up to 20 residues per second in prokaryotes at 37 °C [46] and slower in eukaryotes [47]) and the rate 
of in vitro refolding, the formation of metal-protein complexes is extremely fast; the inner-sphere aquo 
ions of divalent metal ions are substituted with a rate in the range of 10
7–109 s−1 [2]. 
Table 2. IC50 values of Cd
2+
, Hg
2+
, Pb
2+
 and NaAsO2 for the inhibition of protein refolding. 
 
IC50 value (nM) 
Cd
2+
 Hg
2+
 Pb
2+
 NaAsO2 
Luciferase     
Spontaneous refolding 66 ± 11 40 ± 3 63 ± 6 426 ± 4 
Chaperone-assisted refolding 100 ± 5 53 ± 2 140 ± 11 297 ± 13 
Chaperone-mediated disaggregation 280 ± 4 210 ± 16 325 ± 11 613 ± 31 
Lactate dehydrogenase     
Spontaneous refolding 68 ± 2 58 ± 6 74 ± 9 ND 
Malate dehydrogenase     
Spontaneous refolding 300 ± 45 290 ± 16 520 ± 44 ND 
Glucose-6-phosphate dehydrogenase     
Spontaneous refolding 340 ± 15 230 ± 18 >600 ND 
* IC50 values with SEM from three independent experimental datasets [7,9]. The values given are apparent 
values determined at a protein concentration of 350 nM (see text). ND: not determined. 
Observations quite similar to those with heavy metal ions have been reported with the metalloid, 
arsenic. Arsenic(III) compounds have been found to interfere in vitro with the oxidative refolding of 
three different disulfide-containing proteins; lysozyme and ribonuclease with four disulfide bridges 
and riboflavin-binding protein with nine disulfide bridges. Arsenicals at a micromolar concentration 
inhibited the oxidative refolding by formation of bi- and tri-dentate complexes with the cysteine 
residues of the chemically denatured reduced proteins [8]. A subsequent study showed that arsenite 
also interferes with the refolding of chemically denatured luciferase, which contains four free cysteine 
residues and no disulfide bridge [9]. Arsenite with an IC50 in the three-digit micromolar range is a 
considerably less effective inhibitor of in vitro protein refolding than heavy metal ions. However, the 
consequences of arsenite and heavy metals interfering with protein refolding in vitro are similar;  
in both cases, β-structured aggregates of inactive misfolded proteins are produced with an enhanced 
affinity for thioflavin-T [7,8]. The aggregation might not only be due to intermolecular hydrophobic 
interactions of metal-induced misfolded proteins, but might in part also be initiated by metal ions 
complexing with two polypeptide chains at the same time. The metal-induced aggregates (after gel 
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filtration to remove uncomplexed metal ions) have a seeding capacity and promote the aggregation of 
refolding protein without the de novo addition of metal ions [9,48]. 
Xenobiotic heavy metals and metalloids other than those tested, as well as essential heavy metals in 
an overdose may also be expected to perturb protein folding. Indeed, it has been observed that the  
in vitro renaturation of chemically denaturated metal-free alcohol dehydrogenase is inhibited by Zn2+ 
in an overdose. The inhibition was suggested to be due to the blocking of an inactive intermediate in an 
incorrect conformation [49]. 
5. Heavy Metals and Metalloids Interfere with Protein Folding and Induce Protein Aggregation 
in Living Cells 
As discussed above, certain heavy metals and metalloids potently inhibit protein folding in vitro. 
Recent work in yeast demonstrated that this mode of action also occurs in living cells [9,48,50]. 
Saccharomyces cerevisiae (budding yeast) cells accumulated aggregated proteins following exposure 
to equi-toxic concentrations of arsenite, cadmium and chromium (Cr(VI)) in the order As > Cd > Cr [9]. 
The in vivo potency of these agents to trigger protein aggregation probably depends on the efficiency 
of their cellular uptake/export and on their distinct modes of biological action. Arsenite-induced 
protein aggregation was shown to be concentration-dependent, and the aggregates contained a wide 
variety of proteins enriched in functions related to protein synthesis, metabolism and protein folding 
and stabilization. Notably, these aggregates are largely distinct from so-called processing bodies  
(P-bodies) and stress granules, structures known to form in response to arsenite exposure. Several 
chaperones co-sedimented with the aggregates, indicating that arsenite promotes protein misfolding  
in vivo. Indeed, arsenite was demonstrated to interfere with protein folding in living cells in two ways. 
Firstly, arsenite affected the folding of nascent proteins during the processes of translation, likely by 
acting on not yet folded segments of the polypeptide chain; secondly, it directly inhibited chaperone 
activity [9] (the chaperone(s) targeted remain unidentified for the time being). One probable target is 
the CCT (chaperonin-containing T) complex, since arsenite inhibits CCT activity in vitro [51] and 
several components of the CCT complex have been found among the arsenite-aggregated proteins [9]. 
Other putative targets include the ribosome-associated Hsp70s Ssb1p and Ssb2p, as well as cytosolic 
Ssa1p; these yeast chaperones contain surface-exposed reactive cysteine residues [52] and have been 
found among arsenite-aggregated proteins [9]. Thus, arsenite might directly bind to or modify critical 
cysteine residues and thereby inhibit the activity of these chaperones. In this respect, the ribosome-associated 
Hsp70s Ssb1p and Ssb2p are of particular interest, because a major fraction of the proteins that aggregate 
in yeast cells following arsenite exposure appear to be co-translational substrates of Ssb2p [50]. Hence, 
besides acting on nascent polypeptides during translation, arsenite may also target chaperones for 
inactivation and/or aggregation, thereby diminishing the overall folding capacity of the cell. Both 
mechanisms of arsenite action will lead to widespread protein misfolding and aggregation. 
Arsenite-induced protein aggregation correlates with the toxicity of the metalloid [9]; however, it is 
not entirely understood how these aggregates affect cell viability. Toxicity could potentially be caused 
by the depletion of individual proteins that aggregate. However, the overlap between yeast proteins 
that aggregate during arsenite exposure and the arsenite sensitivity of the corresponding gene deletion 
mutants is poor, suggesting that inactivation/depletion of individual proteins by aggregation, i.e., by 
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loss of function, is not a major toxicity mechanism. On the other hand, the proteins that aggregate upon 
arsenite exposure are enriched for multiple protein-protein interactions [50], suggesting that misfolded 
forms of these proteins might engage in extensive aberrant protein-protein interactions during 
exposure, thereby affecting cell viability. Consistent with this notion, in vitro data indicate that 
arsenite-induced protein aggregates, in a gain-of-function mechanism, act as seeds committing other, 
labile proteins to misfold and aggregate [9]. 
Widespread aggregation of nascent proteins is also observed in cadmium-exposed yeast cells [9,48,53]. 
In addition, cadmium has been shown to cause endoplasmic reticulum (ER) stress in yeast [54] and 
probably also in mammalian cells [55–58]. Neither arsenite nor mercury provoke any ER stress in 
yeast [54]. ER stress is characterized by an accumulation of unfolded proteins in the ER, which, in 
turn, activates the unfolded protein response (UPR). The UPR, which is operative in most eukaryotic 
cells from yeast to mammals, induces the expression of proteins that facilitate protein folding in the 
ER, thus mitigating the ER stress [59]. Yeast mutants that cannot induce the UPR are hypersensitive to 
cadmium, suggesting that toxicity might be a consequence of cadmium accumulation in the ER [54]. 
Whilst cadmium does not interfere with the formation of disulfide bonds in the ER, it appears to 
perturb calcium metabolism [54], a condition that may result in ER stress [60]. The mechanistic details 
of how cadmium causes protein misfolding in the cytosol and the ER remain to be elucidated. 
Chromium (Cr(VI)) has been shown to trigger oxidative protein damage [61] and protein 
aggregation in yeast [9,10]. Whilst arsenite and cadmium directly interfere with protein folding, 
chromium induces protein aggregation by enhancing mRNA mistranslation. Mistranslation appears to 
be a primary cause of cellular chromium toxicity [10]. Although the mechanistic details of how 
chromium provokes mRNA mistranslation remain unknown, misincorporation of amino acids may 
result in misfolding and aggregation of the corresponding proteins. Neither arsenite nor cadmium 
cause mRNA mistranslation to any major extent [9,48]. 
To conclude, these recent studies in yeast demonstrated that heavy metals and metalloids interfere 
with protein folding in living cells through common, as well as distinct mechanisms, nascent or  
non-folded proteins being the prime targets. Quite likely, heavy metals and metalloids other than those 
already tested will perturb protein folding and manifest their toxicity through similar mechanisms. 
6. How Cells Deal with Heavy Metal- and Metalloid-Induced Protein Misfolding and Aggregation 
Protein quality-control systems monitor the correct functionality of the proteome and protect cells 
against the harmful accumulation of protein aggregates during environmental stress conditions, as well 
as during disease and ageing processes [11,20]. In response to heavy metal exposure, cells adjust their 
gene expression programs; (1) chaperone- and other heat-shock-response genes are activated, probably 
to enhance the folding capacity of the cell [62–70]; (2) proteasome-encoding genes are activated to 
enhance the protein degradation capacity of the cells [64–67,71–73]; and (3) the expression of genes 
encoding aggregation-prone proteins is downregulated, presumably to prevent excessive accumulation 
of harmful aggregates [50,74]. Failure to adjust the protein quality-control systems will result in 
increased metal/metalloid sensitivity [9,65–67,75]. 
Thermotolerance in yeast and bacterial cells has been shown to be based on chaperone-mediated 
protein rescue rather than the degradation of aggregated proteins [76,77]. Albeit chaperones and other 
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heat-shock proteins are induced by heavy metals and metalloids, it is not clear to what extent the 
rescuing of proteins contributes to tolerance. Arsenite exposure results in enhanced expression of the 
disaggregating chaperone, Hsp104p, as well as other heat-shock proteins in yeast [9,65,70]; however, 
whilst yeast cells lacking Hsp104p are 100- to 1,000-fold more sensitive to heat than wild-type cells, 
Hsp104p provides only a two- to three-fold survival advantage during exposure to lethal 
concentrations of arsenite [70]. Likewise, Hsp104p is strongly induced by cadmium, but contributes 
little, if anything, to cadmium tolerance [70]. There are several ways to interpret these observations. 
From an aggregation point of view, aggregates produced by heat, on the one hand, and 
cadmium/arsenite, on the other hand, may be fundamentally dissimilar. From a toxicity point of view, 
the main lesion produced by arsenite and cadmium may not be accessible to Hsp104p (e.g., different 
compartments) or may not be a protein. From a chaperone point of view, arsenite and cadmium may 
directly inhibit Hsp104p or other chaperones required to restore folding homeostasis. The latter mechanism 
may account for the poor performance of Hsp104p in arsenite tolerance [70] and its inability to dissolve 
aggregates when this metalloid is present [9]. 
The capacity to degrade misfolded proteins is important during stress conditions and for protecting 
cells against a variety of protein misfolding disorders [78]. The ubiquitin-proteasomal system mediates 
the degradation of metal-induced protein aggregates and is clearly important for heavy metal tolerance in 
yeast: cadmium-treated cells enhance protein degradation rates via the ubiquitin-proteasome pathway [53]; 
arsenite-exposed cells increase proteasomal activity and clear the cytosol from arsenite-induced 
aggregates primarily via proteasomal degradation [9,79]; and yeast cells with diminished proteasomal 
activity are sensitized toward arsenite, cadmium and chromium [9,10,67,75,80]. Proteasomal activity 
can be controlled both at the transcriptional and post-translational level. For instance, yeast cells 
induce the expression of proteasome-encoding genes in response to arsenite exposure and, thus, 
enhance proteasomal activity [9]. Upon arsenite exposure, yeast appear to regulate proteasomal 
activity also at the post-transcriptional level [9]. The mechanistic details of this regulation are currently 
unknown. Mammalian cells induce the expression of the AIRAP protein in response to arsenite 
exposure. AIRAP interacts with the proteasome to enhance its stability and/or activity [71]. The 
mechanism of how AIRAP regulates the proteasome function is unclear. 
Chelation and complexation is another strategy that cells utilize to deal with toxic metals and 
metalloids. Yeast exposed to arsenite, cadmium or chromium induce the expression of genes in the 
glutathione (GSH) biosynthesis pathway and accumulate high amounts of reduced GSH [65,66,81–84]. 
Amongst other mechanisms, GSH contributes to metal detoxification by complexing metal ions. 
Metal-GSH complexes are recognized by membrane-bound transporters that catalyze their export out 
of cells or their sequestration in an intracellular compartment [5,85]. In addition, GSH protects the 
proteome against arsenite-induced aggregation; yeast cells deficient in GSH biosynthesis accumulated 
more aggregated proteins than wild-type cells upon arsenite exposure, whereas cells with increased 
arsenite-chelating capacity accumulated fewer aggregates [86]. Thus, by complexing arsenite, GSH 
lowers the levels of free metalloid in the cytosol and prevents it from interacting with nascent proteins. 
Other metal-binding agents, such as metallothioneins (present in a wide range of organisms from 
bacteria to mammalian cells) or phytochelatins (present in plants and some fungi) are known to buffer 
metal ions via sequestration [1]. Thus, metallothioneins and phytochelatins act to keep the cellular 
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concentration of free metal ions low and might therefore also prevent interactions between metals and 
nascent proteins. 
It has been suggested that aggregation is an intrinsic property of all proteins and that proteins are 
only just soluble at the concentration levels at which they are expressed in the cell [87]. Accordingly, 
yeast proteins predicted to be aggregation-prone appear to be kept at concentrations below a critical 
threshold that would prevent their aggregation [74]. Moreover, the expression of the proteins that were 
found to aggregate in yeast cells following arsenite exposure was downregulated in the presence of the 
metalloid [50]. Whether downregulation of these proteins protects cells from excessive misfolding and 
aggregation remains to be demonstrated. Nevertheless, the data above suggests that cells may sense 
and signal disturbed protein homeostasis to the transcriptional machinery. The sensing and signaling 
mechanisms that control this response are currently unknown. 
Another means to protect the intracellular environment from potentially toxic protein species is to 
sequester aggregated proteins to specific deposit sites. Yeast and mammalian cells relocate misfolded 
proteins that are ubiquitylated to a juxtanuclear quality-control compartment (JUNQ), where they are 
processed for degradation, whilst non-ubiquitylated proteins are diverted to peripheral insoluble 
protein deposits (IPOD) [88]. Whether heavy metal/metalloid-induced aggregates are sequestered to 
specific deposit sites, like JUNQ and/or IPOD, has not been explored as yet. 
Finally, the most prominent heavy metal/metalloid tolerance mechanism is provided by a range of 
membrane-bound transporters that remove xenobiotic agents from the cytosol either by catalyzing  
their export out of the cell or by catalyzing their sequestration into intracellular compartments [1].  
The activity of such export pathways decreases cytosolic levels of metals/metalloids and protects the 
intracellular environment from metal damage. Indeed, overexpression of an arsenite export protein in 
yeast has been shown to diminish intracellular arsenic levels and to prevent protein aggregation [9]. 
7. Metal-Induced Protein Aggregation and Protein Misfolding Disorders 
Protein misfolding and aggregation are molecular hallmarks of several neurodegenerative and  
age-related disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis and Parkinson’s 
disease. In these disease states, specific proteins adopt non-native conformations and aggregate.  
In addition, aberrant interactions between disease-associated and other cellular proteins might  
lead to extensive co-aggregation and loss of function of non-disease proteins [11,13]. There is  
accumulating evidence that heavy metals and metalloids may influence the aggregation properties of 
disease-associated proteins and promote certain neurodegenerative diseases through largely unknown 
mechanisms [14–19,89,90]. The mechanism of toxic action described here suggests that the deleterious 
effects of heavy metals and metalloids may result from short-term, direct interactions of metal ions 
with folding proteins. Additionally, long-term interactions of low concentrations of metal-induced seed 
aggregates may prompt other labile proteins to misfold and aggregate [9]. In mammals, these effects 
may become amplified with age when the efficiency of chaperone- and protease-dependent 
proteostasis mechanisms declines [91]. Remarkably, several yeast proteins that aggregate in response 
to arsenite have human homologues that are present in aggregates associated with protein folding 
disorders [50]. Hence, the effects of arsenic, as well as heavy metals described here might contribute to 
protein misfolding disorders. 
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8. Perspectives 
It is becoming increasingly clear that heavy metals and metalloids profoundly affect protein 
homeostasis and cell viability by interfering with protein folding processes in living cells. This 
mechanism of toxicity does not only affect individual proteins, but also results in the formation  
and cellular accumulation of toxic protein aggregates. Chronic metal exposure is associated with  
age-related and neurodegenerative disorders caused by aberrant protein folding. A detailed 
understanding of the molecular mechanisms by which metals interfere with protein folding and 
promote protein aggregation in vivo, how aggregates impair cellular functions, how cells regulate the 
protein quality-control systems to protect against aggregate toxicity and how these processes are linked 
to disease pathologies may ultimately contribute to the development of new strategies for the 
prevention and treatment of protein misfolding disorders. 
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